IL-1 antagonist formulations
US7572893B2 · kind B2 · utility
5Cited by
5References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 18, 2007 |
| Grant date | Aug 11, 2009 |
| Priority date | — |
| Expiry date | Sep 25, 2027 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/0019
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Formulations of an interleukin-1 (IL-1) antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the IL-1 antagonist is an IL-1 trap composed of a dimer of two fusion protein having an amino acid sequence selected from the group consisting of SEQ ID NO: 10.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.